التفاصيل البيبلوغرافية
العنوان:
Minimal residual disease-directed therapy in acute myeloid leukemia
المؤلفون:
David Grimwade , Richard F. Schlenk , Roland B. Walter , Sabine Kayser , Victor E. D. Yosuico
المصدر:
Blood . 125(15)
سنة النشر:
2014
مصطلحات موضوعية:
Adult , Male , Myeloid , Neoplasm, Residual , Oncogene Proteins, Fusion , medicine.medical_treatment , Immunology , Antineoplastic Agents , Hematopoietic stem cell transplantation , Biochemistry , Fusion gene , RUNX1 Translocation Partner 1 Protein , hemic and lymphatic diseases , medicine , Humans , business.industry , Cytarabine , Hematopoietic Stem Cell Transplantation , Myeloid leukemia , Cell Biology , Hematology , medicine.disease , Virology , Minimal residual disease , Leukemia , Leukemia, Myeloid, Acute , medicine.anatomical_structure , Real-time polymerase chain reaction , Core Binding Factor Alpha 2 Subunit , Cancer research , Female , business , Idarubicin
الوصف:
Case 1: A 35-year-old man with a normal white blood cell (WBC) count (9.3 × 10 9 /L) was diagnosed with acute myeloid leukemia (AML) with a t(8;21)(q22;q22) translocation in 25/25 metaphases. The RUNX1-RUNX1T1 fusion gene was detected by real-time quantitative polymerase chain reaction (PCR)
تدمد:
1528-0020
الوصول الحر:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a7b93734df6141984ab3fb46a554872Test https://pubmed.ncbi.nlm.nih.gov/25631772Test
حقوق:
OPEN
رقم الانضمام:
edsair.doi.dedup.....0a7b93734df6141984ab3fb46a554872
قاعدة البيانات:
OpenAIRE
